HYPRNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Hyperfine, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.78+0.02 (+2.97%)
Close on Oct 19, 2026
- Market cap
- $77.56M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
49.8%+212.0 pts over 5 years
Operating margin
-273.4%+7716.7 pts over 5 years
Net margin
-262.3%+7706.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.2% | +25.8% | +115.2% | – | |
| Gross profit | +14.6% | +95.3% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 46.4% | -79.0% | |
| Return on assets | – | – | -62.3% | |
| Current ratio | – | 16.60 | 4.34 | |
| Debt to equity | – | -0.00 | 0.00 | |
| Inventory turnover | – | – | 1.1× | |
| Capex to revenue | – | 533.3% | 8.7% | |
| Diluted shares | – | 2M | 82M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Hyperfine generated $228.05M from operations and spent $5.67M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$228.05M
Used
$5.67M
Capital expenditure$5.67M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-262.3%
×Asset turnover0.24×
×Equity multiplier1.27×
=Return on equity, FY2025-79.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -262.3% | 0.24× | 1.27× | -79.0% |
| FY2024 | -315.9% | 0.17× | 1.15× | -61.0% |
| FY2023 | -401.0% | 0.10× | 1.10× | -42.5% |
| FY2022 | -649.2% | 0.04× | 1.09× | -28.5% |
| FY2021 | -4335.0% | 0.01× | 2.19× | -103.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$35.57M
- Cash generatingOperating cash flow above zero-$27.95M
- Return on assets improvedROA up on the prior year-43.2% → -60.4%
- Earnings backed by cashOperating cash flow above net income-$27.95M vs -$35.57M
- Less leverageLong-term debt to assets fell– → 0.0%
- Better liquidityCurrent ratio rose6.15 → 4.34
- No dilutionShare count did not rise72M → 82M
- Gross margin improvedGross margin up on the prior year45.70% → 49.79%
- More efficientAsset turnover rose0.14 → 0.23